Theodore L. Roth

Affiliations: 
Stanford University, Palo Alto, CA 
 UCSF School of Medicine 
 National Institutes of Health-NINDS 
Google:
"Theodore Roth"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Nguyen DN, Roth TL, Li PJ, et al. (2019) Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nature Biotechnology
Ng MSF, Roth TL, Mendoza VF, et al. (2019) Helios enhances the preferential differentiation of human fetal CD4 naïve T cells into regulatory T cells. Science Immunology. 4
Leenay RT, Aghazadeh A, Hiatt J, et al. (2019) Large dataset enables prediction of repair after CRISPR-Cas9 editing in primary T cells. Nature Biotechnology
Schober K, Müller TR, Gökmen F, et al. (2019) Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nature Biomedical Engineering
Simeonov DR, Brandt AJ, Chan AY, et al. (2019) A large CRISPR-induced bystander mutation causes immune dysregulation. Communications Biology. 2: 70
Hultquist JF, Hiatt J, Schumann K, et al. (2019) CRISPR-Cas9 genome engineering of primary CD4 T cells for the interrogation of HIV-host factor interactions. Nature Protocols. 14: 1-27
Shifrut E, Carnevale J, Tobin V, et al. (2018) Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. Cell
Mocciaro A, Roth TL, Bennett HM, et al. (2018) Light-activated cell identification and sorting (LACIS) for selection of edited clones on a nanofluidic device. Communications Biology. 1: 41
Roth TL, Puig-Saus C, Yu R, et al. (2018) Reprogramming human T cell function and specificity with non-viral genome targeting. Nature
Simeonov DR, Gowen BG, Boontanrart M, et al. (2018) Author Correction: Discovery of stimulation-responsive immune enhancers with CRISPR activation. Nature
See more...